Advanced Accelerator Applications announced today its financial results for the first quarter of 2015. The company reported an increase in year-on-year sales of 24.5% for Q1 2015 compared to Q1 2014.
Other key news includes the FDA Fast Track Designation for Lutathera for the treatment of midgut neuroendocrine tumors.
Commenting on the first quarter performance, AAA’s CEO Stefano Buono said: “I am pleased to announce that AAA is performing according to plans or better on both financial and clinical fronts. AAA continues to establish efficiencies in manufacturing, logistics, and financial discipline as we prepare for our global launch of Lutathera.”
“We believe that Lutathera provides the potential to significantly impact how physicians treat NETs overexpressing somatostatin receptors in the near future. The Fast Track Designation received from the FDA is an important step in broadening the treatment options for these patients, and highlights the significant impact nuclear medicine can play within the treatment paradigm. We expect the results to demonstrate a clinically important and statistically robust improvement in progression-free survival for patients treated with Lutathera.”